Compare CFFN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | MNKD |
|---|---|---|
| Founded | 1893 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 877.0M |
| IPO Year | 2010 | 2004 |
| Metric | CFFN | MNKD |
|---|---|---|
| Price | $7.79 | $3.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.25 | ★ $8.69 |
| AVG Volume (30 Days) | 858.4K | ★ 5.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | $16,300,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $20.16 | $35.81 |
| Revenue Next Year | $6.62 | $11.89 |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | 6.54 | ★ 22.23 |
| 52 Week Low | $5.51 | $2.23 |
| 52 Week High | $7.97 | $6.51 |
| Indicator | CFFN | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 64.76 |
| Support Level | $7.47 | $3.39 |
| Resistance Level | $7.84 | $6.08 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 60.22 | 47.06 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.